TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer

Abstract Breast cancer (BC) is a common malignancy that affects women worldwide. Although transducing beta‐like 2 (TBL2), a member of the WD40 repeat protein family, has been implicated in various intracellular signaling pathways, its precise function in BC remains unclear. The expression of TBL2 is...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiuqing Lu, Chao Zhang, Lewei Zhu, Sifen Wang, Lijun Zeng, Wenjing Zhong, Xuxia Wu, Qi Yuan, Hailin Tang, Shien Cui, Yeru Tan, Yuehua Li, Weidong Wei
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202400160
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850248469732655104
author Xiuqing Lu
Chao Zhang
Lewei Zhu
Sifen Wang
Lijun Zeng
Wenjing Zhong
Xuxia Wu
Qi Yuan
Hailin Tang
Shien Cui
Yeru Tan
Yuehua Li
Weidong Wei
author_facet Xiuqing Lu
Chao Zhang
Lewei Zhu
Sifen Wang
Lijun Zeng
Wenjing Zhong
Xuxia Wu
Qi Yuan
Hailin Tang
Shien Cui
Yeru Tan
Yuehua Li
Weidong Wei
author_sort Xiuqing Lu
collection DOAJ
description Abstract Breast cancer (BC) is a common malignancy that affects women worldwide. Although transducing beta‐like 2 (TBL2), a member of the WD40 repeat protein family, has been implicated in various intracellular signaling pathways, its precise function in BC remains unclear. The expression of TBL2 is analyzed using real‐time PCR, western blotting, and immunohistochemistry in BC patient specimens. Kaplan–Meier survival analysis is employed to assess its prognostic significance. Proteomic analysis, immunoprecipitation tests, and protein immunoblotting are employed to examine the impact of TBL2 on AKT phosphorylation activation. The findings reveal selective overexpression of TBL2 in BC, correlating significantly with various clinicopathological characteristics and poor survival outcomes in patients with BC. Through in vivo and in vitro experiments, it is observed that TBL2 suppression inhibits BC cell proliferation, while TBL2 overexpression has the opposite effect. Mechanistically, TBL2 is identified as a scaffolding protein that promotes PRMT5 and WDR77 interaction. This interaction enhances the methyltransferase activity of PRMT5, leading to increased AKT phosphorylation activation and promotion of breast cancer cell proliferation. In conclusion, this study uncovers a novel function of TBL2 in the activation of AKT by PRMT5 and suggests TBL2 as a potential therapeutic target for BC treatment.
format Article
id doaj-art-60f8922a631346529072cf07536e6786
institution OA Journals
issn 2198-3844
language English
publishDate 2024-12-01
publisher Wiley
record_format Article
series Advanced Science
spelling doaj-art-60f8922a631346529072cf07536e67862025-08-20T01:58:42ZengWileyAdvanced Science2198-38442024-12-011147n/an/a10.1002/advs.202400160TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast CancerXiuqing Lu0Chao Zhang1Lewei Zhu2Sifen Wang3Lijun Zeng4Wenjing Zhong5Xuxia Wu6Qi Yuan7Hailin Tang8Shien Cui9Yeru Tan10Yuehua Li11Weidong Wei12State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaDepartment of Breast Surgery The First People's Hospital of Foshan Foshan Guangdong 528000 ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaThe First Affiliated Hospital Hengyang Medical School University of South China Hengyang Hunan 421001 ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaDistrict 2 Breast Center Zhongshan City People's Hospital Zhongshan 528400 ChinaThe First Affiliated Hospital Hengyang Medical School University of South China Hengyang Hunan 421001 ChinaThe First Affiliated Hospital Hengyang Medical School University of South China Hengyang Hunan 421001 ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou Guangdong 510000 ChinaAbstract Breast cancer (BC) is a common malignancy that affects women worldwide. Although transducing beta‐like 2 (TBL2), a member of the WD40 repeat protein family, has been implicated in various intracellular signaling pathways, its precise function in BC remains unclear. The expression of TBL2 is analyzed using real‐time PCR, western blotting, and immunohistochemistry in BC patient specimens. Kaplan–Meier survival analysis is employed to assess its prognostic significance. Proteomic analysis, immunoprecipitation tests, and protein immunoblotting are employed to examine the impact of TBL2 on AKT phosphorylation activation. The findings reveal selective overexpression of TBL2 in BC, correlating significantly with various clinicopathological characteristics and poor survival outcomes in patients with BC. Through in vivo and in vitro experiments, it is observed that TBL2 suppression inhibits BC cell proliferation, while TBL2 overexpression has the opposite effect. Mechanistically, TBL2 is identified as a scaffolding protein that promotes PRMT5 and WDR77 interaction. This interaction enhances the methyltransferase activity of PRMT5, leading to increased AKT phosphorylation activation and promotion of breast cancer cell proliferation. In conclusion, this study uncovers a novel function of TBL2 in the activation of AKT by PRMT5 and suggests TBL2 as a potential therapeutic target for BC treatment.https://doi.org/10.1002/advs.202400160AKT phosphorylationbreast cancerPRMT5/WDR77proliferationTBL2
spellingShingle Xiuqing Lu
Chao Zhang
Lewei Zhu
Sifen Wang
Lijun Zeng
Wenjing Zhong
Xuxia Wu
Qi Yuan
Hailin Tang
Shien Cui
Yeru Tan
Yuehua Li
Weidong Wei
TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
Advanced Science
AKT phosphorylation
breast cancer
PRMT5/WDR77
proliferation
TBL2
title TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
title_full TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
title_fullStr TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
title_full_unstemmed TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
title_short TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
title_sort tbl2 promotes tumorigenesis via prmt5 wdr77 mediated akt activation in breast cancer
topic AKT phosphorylation
breast cancer
PRMT5/WDR77
proliferation
TBL2
url https://doi.org/10.1002/advs.202400160
work_keys_str_mv AT xiuqinglu tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT chaozhang tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT leweizhu tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT sifenwang tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT lijunzeng tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT wenjingzhong tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT xuxiawu tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT qiyuan tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT hailintang tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT shiencui tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT yerutan tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT yuehuali tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer
AT weidongwei tbl2promotestumorigenesisviaprmt5wdr77mediatedaktactivationinbreastcancer